Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus Vaccine (RSVPreF3) in Mothers and Their Infants: A Phase 2 Randomized Trial

Overview of attention for article published in Journal of Infectious Diseases, February 2023

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (96th percentile)
High Attention Score compared to outputs of the same age and source (90th percentile)

Mentioned by

news: 4 news outlets
blogs: 1 blog
twitter: 9 X users

reddit: 1 Redditor
podcasts: 1 podcast

Readers on

mendeley: 111 Mendeley

So far, Altmetric has seen 12 X posts from 9 X users, with an upper bound of 148,318 followers.

あ、RSワクチンでした。間違えました。わずかに早産リスクは上がる可能性はあるが、メリットが上回ると結論づけられてますね。 RSウイルスワクチン（RSVPreF3）の母子における安全性と免疫原性：第2相ランダム化試験 https://t.co/e9EZjrfx2R RSVPreF3 母親のワクチン接種…

RT @JIDJournal: Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus Vaccine (RSVPreF3) in Mothers and Their Infants…

Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus Vaccine (RSVPreF3) in Mothers and Their Infants: A Phase 2 Randomized Trial 🔓 Open Access 🔗 https://t.co/jVEJ3T0IFZ https://t.co/GCBKv1HoT8

Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus Vaccine (RSVPreF3) in Mothers and Their Infants: A Phase 2 Randomized Trial ✅ Just Accepted 🔓 Open Access 🔗 https://t.co/jVEJ3T0aQr https://t.co/2CHkTFbOgo

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 8 additional X posts.